Reducing Prescription Opioid Misuse: ROPEs Pilot Trial
Tracking Information | |||
---|---|---|---|
First Submitted Date ICMJE | September 27, 2018 | ||
First Posted Date ICMJE | October 2, 2018 | ||
Last Update Posted Date | October 4, 2018 | ||
Actual Study Start Date ICMJE | January 2019 | ||
Estimated Primary Completion Date | August 2019 (Final data collection date for primary outcome measure) | ||
Current Primary Outcome Measures ICMJE |
Methodological Feasibility: Recruitment Rate[ Time Frame: Baseline completion, approximately 2 hours ] Number of Participants Recruited Methodological Feasibility: Completion Rates[ Time Frame: Baseline completion, approximately 2 hours ] Percent of Patients Completing ROPES (or control) Methodological Feasibility: Follow-Up Completion Rates[ Time Frame: Through study completion, an average of 4-6 weeks (Baseline and one-month follow-up) ] Percent of baseline participants completing the one-month follow-up assessment Methodological Feasibility: Time to Complete Intervention[ Time Frame: Baseline completion component, approximately 90 minutes ] Time participant takes to finish engaging with ROPES intervention or control intervention |
||
Original Primary Outcome Measures ICMJE | Same as current | ||
Current Secondary Outcome Measures ICMJE |
|
||
Descriptive Information | |||
Brief Title ICMJE | Reducing Prescription Opioid Misuse: ROPEs Pilot Trial |
||
Official Title ICMJE | Reducing Prescription Opioid Misuse: Dental Provider Intervention Development |
||
Brief Summary | This is a randomized controlled pilot trial to establish methodological feasibility and determine whether a web-based, continuing dental education intervention regarding opioid prescribing risk mitigation strategies - consistent with ADA guidelines - produces pre-to-post changes in knowledge, motivation, and behavioral skills pertaining to the use of risk mitigation strategies when prescribing opioids in dental practice. The current study involves completion of a self-report pre-test (dentists), randomization to complete ROPEs or attention control intervention, completion of a self-report post-test (immediately following intervention/control completion), and completion of 1-month self-report follow-up assessment. |
||
Detailed Description | |||
Study Type ICMJE | Interventional | ||
Study Phase | N/A | ||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Masking: Interventional Masking Description: Primary Purpose: Other |
||
Condition ICMJE | |||
Intervention ICMJE |
|
||
Study Arms |
|
||
Recruitment Information | |||
Recruitment Status ICMJE | Not yet recruiting | ||
Estimated Enrollment ICMJE |
60 | ||
Original Estimated Enrollment ICMJE | Same as current | ||
Estimated Study Completion Date | August 2019 | ||
Estimated Primary Completion Date | August 2019 (Final data collection date for primary outcome measure) | ||
Eligibility Criteria ICMJE | Inclusion Criteria: 1. Male or female; any race or ethnicity; age 21-85 years. 2. Able to comprehend English. 3. Be either a licensed dental practitioner currently practicing or a Resident enrolled in the College of Dental Medicine at the Medical University of South Carolina or a practicing dentist in the Charleston-county area or a licensed dental practitioner currently participating in the National Dental Practice Based Research Network (NDPBRN). 4. Report having ever prescribed an opioid analgesic to a patient 5. Must have Internet access 6. Must have a valid, usable email account 7. Must agree to complete all study measurements. Exclusion Criteria: 1. Unable to provide informed consent due to mental or physical limitations. 2. Participation in ROPEs intervention development focus groups. | ||
Sex/Gender |
|
||
Ages | 18 Years and older (Adult, Older Adult) | ||
Accepts Healthy Volunteers | No | ||
Listed Location Countries ICMJE | |||
Removed Location Countries | |||
Administrative Information | Has Data Monitoring Committee | Yes | |
U.S. FDA-regulated Product |
Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No |
||
IPD Sharing Statement |
|
||
Responsible Party | Jenna McCauley,Medical University of South Carolina | ||
Study Sponsor ICMJE | Medical University of South Carolina | ||
Collaborators ICMJE | |||
Investigators ICMJE |
|
||
PRS Account | Medical University of South Carolina | ||
Verification Date | October 2018 | ||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |